Phase I Trial of GPC3-Targeted TCR Fusion Construct, CT0180, in Patients with Advanced Hepatocellular Carcinoma.
Clin Cancer ResOct 1, 2026
Clinical ResearchOncology (Medical)
Xuqi Sun, Wanwan Gao, Chunhui Shou et al.
✦ AI-curated · Sources linked
In 30 seconds
This Phase I open-label trial evaluated the safety and preliminary efficacy of CT0180, a GPC3-targeted TCR fusion construct, in patients with advanced hepatocellular carcinoma (HCC) who had progressed on standard therapies. Among seven patients, the objective response rate was 28.6%, with a median overall survival of 11.6 months.
Key findings
- Objective response rate of 28.6% with two patients achieving partial responses.
- Disease control rate of 71.4%, with three patients achieving stable disease.
- Median progression-free survival was 7.6 months and overall survival was 11.6 months.
- Cytokine release syndrome occurred in 85.7% of patients, all grade 1.
Why it matters
The study highlights a potential new treatment option for advanced HCC, a condition with limited effective therapies. The manageable safety profile and observed clinical activity warrant further investigation.